CrystalGenomics will provide new pharmaceutical candidate compounds while Bausch & Lomb will develop product formulations, conduct pre-clinical and clinical studies, and bring the products to market. Praveen Tyle,
The convertible preferred stock will be issued in a tax- deferred transaction and provides for a three percent dividend. The total transaction consideration will be approximately $1.18 billion,
The primary endpoint of the study was patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201. N30-201
The AngioSculpt Scoring Balloon Catheter is said to represent the next generation in angioplasty catheters. Its innovative nitinol element provides unique anti-slipping properties while circumferentially dilating plaque, providing
The FDA informed Medivation that the company’s previously completed trial conducted in Russia can be used as one of the two pivotal studies required to support the approval
The data presented at the 2008 Gastrointestinal Cancers Symposium included safety data from a Phase I study of picoplatin in combination with 5-fluorouracil (5FU) and leucovorin (LV) as
Mevacor over-the-counter (OTC) had been under review by the FDA since 1999. Advisory Committee reviews in 2000 and 2005 resulted in not approvable actions. The FDA has indicated
This agreement formalizes the collaboration between the two pharmaceutical laboratories specializing in research on natural substances. It involves bringing together two complementary areas of expertise. The Pierre Fabre
The drug is indicated for treatment of pediatric patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone, or treatment of short stature
The Zydus-Prolong agreement seeks to increase productivity in the drug development of this next generation therapeutic protein by leveraging the combined strengths of both companies. Under the terms
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.